Finance

Lists
Why is STOK down 5,62%?
Dive Deeper
STOK:NASDAQ
Stoke Therapeutics Inc
26,20 $
-5,62%
(-1,56) 1D
26,20 $
0,00% (0,00)
After hours
Closed: 12 նոյ, 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for STOK...
Open
27,51 $
High
27,70 $
Low
26,14 $
Mkt. cap
1,71 մլրդ
Avg. vol.
1,21 մլն
Volume
0,00
52-wk high
40,22 $
52-wk low
22,05 $
EPS
-3,78 $
Beta
1,36
Shares outstanding
65,41 մլն
No. of employees
170
Open
27,51 $
High
27,70 $
Low
26,14 $
Mkt. cap
1,71 մլրդ
Avg. vol.
1,21 մլն
Volume
0,00
52-wk high
40,22 $
52-wk low
22,05 $
EPS
-3,78 $
Beta
1,36
Shares outstanding
65,41 մլն
No. of employees
170
News stories
From web sources and news partners
About Stoke Therapeutics Inc
CEO-
Employees170
Founded2014
HeadquartersBedford, Մասսաչուսեթս, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Analyst ratings
Based on 8 analysts giving stock ratings to STOK in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for STOK in the last 3 months.
Highest
Current 26,20 $
60,00 $ (+129,01%)
Average
48,75 $ (+86,07%)
Lowest
39,00 $ (+48,85%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
50,00 $
+90,8%
11/02/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
58,00 $
+121,4%
11/02/2026
Thomas Shrader
BTIG
Buy
Maintained
39,00 $
+48,9%
11/01/2026
Unknown Analyst
Wedbush
Buy
Maintained
40,00 $
+52,7%
10/30/2026
Kevin Strang
Goldman Sachs
Buy
Maintained
43,00 $
+64,1%
10/30/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
60,00 $
+129%
10/29/2026
Yaron Werber
TD Cowen
Buy
Reiterated
60,00 $
+129%
10/13/2026
Jessica Fye
J.P. Morgan
Buy
Initiated
40,00 $
+52,7%
08/21/2026
Rudy Li
Wolfe Research
Buy
Maintained
40,00 $
+52,7%
08/03/2026
Joseph Stringer
Needham
Buy
Maintained
40,00 $
+52,7%
08/04/2026
Keay Nakae
Chardan Capital
Buy
Maintained
35,00 $
+33,6%
08/03/2026
Unknown Analyst
Jefferies
Buy
Maintained
48,00 $
+83,2%
07/06/2026
Marc Goodman
Leerink Partners
Buy
Maintained
-
-
06/02/2026
Laura Chico
Wedbush
Buy
Maintained
38,00 $
+45%
05/08/2026
Yatin Suneja
Guggenheim
Buy
Maintained
60,00 $
+129%
05/07/2026
Last report
29 հոկ, 2026 թ.
Fiscal period
Q3 2026
-1,08 $ / -0,91 $
-18,12%miss
Revenue / Est. (USD)
11,26 մլն / 8,18 մլն
+37,51%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
1,40 մլն
6,23 մլն
9,32 մլն
11,26 մլն
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
41,70 մլն
39,67 մլն
49,50 մլն
59,83 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
21,15 մլն
19,97 մլն
25,25 մլն
28,74 մլն
Operating expense
62,84 մլն
59,65 մլն
74,75 մլն
88,57 մլն
Total operating expenses
62,84 մլն
59,65 մլն
74,75 մլն
88,57 մլն
Operating income
-61,44 մլն
-53,42 մլն
-65,43 մլն
-77,32 մլն
Other non operating income
-110,00 հզր
18,00 հզր
308,00 հզր
6,00 հզր
EBT including unusual items
-57,93 մլն
-50,00 մլն
-61,62 մլն
-73,64 մլն
EBT excluding unusual items
-57,93 մլն
-50,00 մլն
-61,62 մլն
-73,64 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-57,93 մլն
-50,00 մլն
-61,62 մլն
-73,64 մլն
Net profit margin
-4 132,24%
-802,75%
-660,78%
-654,32%
Earnings per share
-0,97
-0,79
-0,93
-1,08
Interest and investment income
3,62 մլն
3,42 մլն
3,52 մլն
3,68 մլն
Interest expense
-3,00 հզր
-23,00 հզր
-17,00 հզր
-20,00 հզր
Net interest expenses
3,62 մլն
3,40 մլն
3,50 մլն
3,66 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-61,03 մլն
-52,98 մլն
-64,97 մլն
-76,86 մլն
Gain or loss from assets sale
153,00 հզր
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google Apps